Merck launches Biosimilars Clarified, a new online educational resource about biosimilar medicines for patients and the healthcare community
Merck has announced the launch of Biosimilars Clarified, a new educational website for patients, caregivers and the healthcare community that is designed to provide clear, concise and straightforward information about biosimilar medicines. Biosimilars Clarified is designed to help answer questions about biosimilars to the patients to help improve knowledge about the use of biosimilars in the treatment of different diseases.
ABITEC announces extension of product portfolio and enters new market
ABITEC’s R&D continues to develop innovative products that meet the ever evolving demands of the pharmaceutical market. The expansion of their non-ionic High HLB surfactant line, ACCONON®, offers a product that can be used in solid formulation as a high melt emulsifier and bioavailability enhancer. ABITEC is also introducing to market their first line of functional lipid excipients for parenteral applications, INJECTA™.
First human clinical trial for nicotinamide riboside
In the first controlled clinical trial of nicotinamide riboside (NR), a newly discovered form of Vitamin B3, researchers have shown that the compound is safe for humans and increases levels of a cell metabolite that is critical for cellular energy production and protection against stress and DNA damage. The trial showed that the NR vitamin increased NAD+ metabolism by amounts directly related to the dose, and there were no serious side effects with any of the doses. The next step will be to study the effect of longer duration NR supplementation on NAD+ metabolism in healthy adults.
FDA awards 21 grants to stimulate product development for rare diseases
The USFDA Announced that it has awarded 21 new clinical trial research grants totaling more than $23 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry with research spanning domestic and international clinical sites. The FDA awards the grants through the Orphan Products Clinical Trials Grants Program to encourage clinical development of drugs, biologics, medical devices, or medical foods for use in rare diseases.
Corden Pharma Expands Highly Potent API Capabilities
Corden Pharma has completed a new highly potent API process bay for category 4 compounds. This new investment comes after the completion in early 2016 of a new CTD2 facility for the handling (development/manufacturing) of oral solid dosage drug product manufacturing of highly potent and oncology compounds in its Plankstadt (Germany) facility, along with further expansion of capabilities in handling sterile oncology drug products at Latina (Italy).
Juniper Pharma Services Offers Granulation Capabilities
UK-based contract development and manufacturing organization (CDMO) Juniper Pharma Services has added a roller compactor to its enabling technologies platform. The company has purchased a Gerteis Mini-Pactor to expand its granulation capabilities and support recent capability. The Mini-Pactor offers the latest in dry granulation technology, which improves the material handling and processing characteristics of poor-flowing materials, such as amorphous solid dispersions and low dose compounds including potent materials.
The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.
DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial
Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.
The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.
Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%
With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate. Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.
Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and
dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.
For more information on this report email us at info@delveInsight.com.
DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
Global VTE market is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%
Venous Thromboembolism- Market Insights & Drugs Sales Forecast (VTE) -2020: New Report by DelveInsight suggests that the Global VTE market was $4.2 billion in 2015 and expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%.
DelveInsight Report “Venous Thromboembolism-Market Insights & Drugs Sales Forecast Thromboembolism indication. The Report majorly emphasize on the global market size venous thromboembolism. The Report provides Anticoagulants market size and Anticoagulants by 7 Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan) in Venous Thromboembolism indication. The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis,
Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke. Globally the overall incidence for Venous Thromboembolism (VTE) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease. The increasing epidemiology of venous thromboembolism is a key driver for the global anticoagulants market. The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.
The VTE market is distributed among different class of anticoagulants including LMWH, NOACs and Warfarins. Once the patient diagnosed with the DVT or PE, two choices are provided ie warfarin with a parenteral anticoagulant for at least the first 5 days and until the international normalized ratio (INR) is therapeutic or novel oral anticoagulants (NOAC). Xarelto (rivaroxaban) and Eliquis (apixaban) are the preferred therapies due to less major bleeding.
For more information email us at email@example.com
DelveInsight has established its strong presence in therapeutic areas and has launched Analytical Reports on indication, mechanism of actions, drugs, Global API Manufacturers and specialized Reports on Gene Therapy, Anticoagulants, PD-1 and PDL-1, CART and Antibody Drug conjugates.
After tremendous success last year, Delve Insight – Business Consulting & Market Research Company is back again with 2016 updated edition of reports.
Moving forward, this year DelveInsight has broached into new report verticals –Epidemiology and Market Insights in its portfolio.
In addition to that we have also entered into consulting services/custom projects as per interest area of the clients.
DelveInsight’s consulting services includes Market Assessment (Market Size, Market Forecasting and Epidemiology for Indications) & Development Strategies, Competitive Intelligence & Landscaping and Licensing Opportunities.
DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
DelveInsight’s Mechanism of Action Reports has become the Success Reason for the Leading Pharma Companies
In this competitive world, everybody wants to get aware of what others are doing in their sectors and what strategic drivers are followed by the others for the successful future milestones. But the drug future is only dependent on one thing and that is how much efficacy it is showing through its mechanism of action to improve the medical condition. So utilizing the most effective targets and technology, the drug can do million dollar business.
DelveInsight released Mechanism of Action reports provides the targets-mode of action based information-across all the therapy under research work, pipeline products across all the companies, current technology, molecule type, stage, company finances, comparative analysis and therapeutic assessment at every step. These Reports propose specific strategies that could have the most substantial impact in improving R&D productivity.
“We are really happy that our reports are showing potential in the market. We have become a strategic partner for the Pharma Companies worldwide” said Dr. B.K. Agrawal, Managing Partner at DelveInsight Business Research.
These Reports highlights therapeutic targets and their mode of action; for instance Inflammatory targets: Reversible Anticholinesterases, Sphingosine 1-Phosphate (S1P) Inhibitors, c-jun-N-Terminal Kinase (JNK) inhibitors, Cancer Targets: Gamma Secretase inhibitors, IL-13 Receptor Antagonists and many more…..
DelveInsight’s Mechanism of Action reports is not only gaining importance but also has become the most known among the clients.
These reports are available with many resellers like Report Linkers, Report Buyers, Research moz, ASD Reports, Report Stack, Bharat Book Bureau and Market Reports.
Ask for sample reports now!
For more information please contact firstname.lastname@example.org